Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

ABSTRACT:

SUBMITTER: Baselga J 

PROVIDER: S-EPMC5549667 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature